Cargando…
SAT110 Euglycemic Diabetes Ketoacidosis Associated With Sodium-glucose Cotransporter Inhibitors: A Case Series To Raise Awareness
Disclosure: D. Katwal: None. Y. Pokharel: None. M. Ghawji: None. Z. Liu: None. H.O. Steinberg: None. S. Dagogo-Jack: Consulting Fee; Self; AstraZeneca, Boehringer Ingelheim, Janssen Research & Development Company, Medtronic Diabetes, Merck & Co., Sanofi, Bayer, Inc. Research Investigator; Se...
Autores principales: | Katwal, Dilasha, Pokharel, Yasmina, Ghawji, Maher, Liu, Zhao, Steinberg, Helmut O, Dagogo-Jack, Samuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553589/ http://dx.doi.org/10.1210/jendso/bvad114.975 |
Ejemplares similares
-
ODP257 Alpelisib Treatment Associated With Severe Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Aziz, Shima, et al.
Publicado: (2022) -
LBODP036 A Case of Euglycemic Diabetic Ketoacidosis After Distal Pancreatectomy
por: Turner, James, et al.
Publicado: (2022) -
SAT-LB118 Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Arao, Kevin A, et al.
Publicado: (2020) -
ODP175 COVID-19 Induced Euglycemic Diabetic Ketoacidosis in a Patient taking Sodium-Glucose Cotransporter-2 Inhibitors
por: Alqaisi, Sura, et al.
Publicado: (2022) -
ODP192 Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad
por: Nievera, Karl Homer, et al.
Publicado: (2022)